THEMIS MEDICARE LTD. - 530199 - Compliance Certificate Under Regulation 40(9) Of The SEBI (LODR) Regulations, 2015
Enclosed herewith please find Compliance Certificate issued by M/s. V. Laxman & Co Practicing Company Secretaries for the year ended 31st March, 2023 in terms of Regulation 40(9) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. This may be taken as compliance under Regulation 40(9) of the Listing Regulations. THEMIS MEDICARE LTD. - 530199 - Compliance Certificate For The Period Ended March, 2023.
As per the requirement of Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that all activities in relation to both physical and electronic share transfer facility are maintained by the Company's Registrar and Share Transfer Agent, viz., Link Intime India Pvt Ltd a Category-I, Registrar & Share Transfer Agent (RTA), registered with the Securities and Exchange Board of India (SEBI) vide Registration Number: INR000004058 during the period April 1, 2022 to March 31, 2023 (both days inclusive). THEMIS MEDICARE LTD. - 530199 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2023 received from Link lntime India Pvt. Ltd., Registrar and Share Transfer Agent of our Company. This is for your information and record. THEMIS MEDICARE LTD. - 530199 - Closure of Trading Window
We would like to inform you that as per the Company''s minimum Standards Code of Conduct to regulate, monitor and report trading by its Employees and other Connected Persons under SEBI (Prohibition of Insider Trading) Regulations, 2015 (as amended) (PIT Regulations) and pursuant to BSE Circular Ref No: LIST/COMP /01/2019-20 dated 2nd April, 2019 and NSE Circular Ref No. NSE/CML/2019/11 on the provisions of Clause 4 of the Schedule B of the PIT regulations, the Trading Window for dealing in the Securities of the Company shall remain closed on and from 1st April, 2023 and will re-open after completion of 48 hours from the declaration of financial results for the quarter and year ended 31st March, 2023 by the Board of Directors of the Company. This is for your information and record. THEMIS MEDICARE LTD. - 530199 - Receipt Of No Objection From The Drug Controller General Of India'S Office (Central Drug Control Authority ) For Manufacturing And Marketing A Key Product, I.E Diclofenac Injection 75Mg/Ml
With reference to our earlier disclosure dated 12th July, 2018 followed by our updates dated 08th July, 2019and 27th July, 2019, we have to now inform you that the Central Licensing Authority has conveyed its no objection to the Company for manufacturing and marketing a key product, i.e Diclofenac Injection 75mg/ml which the Company had stopped manufacturing and marketing pursuant to a directive from the State Food and Drug Administration authorities. The Company now proposes to examine various options to commercialise the said product and also deal with the pending litigation in consultation with its Legal Advisors. This is for your information and record. THEMIS MEDICARE LTD. - 530199 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
In terms of Regulation 30 of the SEBI (LODR) Regulations, 2015, we are enclosing herewith a copy of the press release titled - Themis Medicare announces DCGI approval of Remifentanil Hydrochloride 1mg/2mg for injection for import and marketing. Kindly take this on record. THEMIS MEDICARE LTD. - 530199 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Listing Regulations') read with part A of Schedule III of the Listing Regulations, we wish to inform that the management of the Company did a one on one physical meeting with Analysts/Investors on Thursday, 16th February 2023; the details of the same are given below: Sr. no. Name Venue 1 Nuvama Wealth Management Themis Office Pursuant to regulation 46(2) of the Listing Regulations, aforesaid information shall be disclosed on the website of the company viz. www.themismedicare.com This is for your information and record. THEMIS MEDICARE LTD. - 530199 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Listing Regulations') read with part A of Schedule III of the Listing Regulations, we wish to inform that the management of the Company will do a one on one physical meeting with Analysts/Investors on Thursday, 16th February 2023; the details of the same are given below: Sr. no. Name Venue 1 Nuvama Wealth Management Themis Office Note: The schedule of the aforesaid meetings is subject to change. The changes may happen due to exigencies on the part of Fund / Broking House / Company. Pursuant to regulation 46(2) of the Listing Regulations, aforesaid information shall be disclosed on the website of the company viz. www.themismedicare.com This is for your information and record. THEMIS MEDICARE LTD. - 530199 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to Regulation 30 and 46 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and with reference to our letter dated 7th February, 2023, intimating you about the earning conference call for Q3 & 9M FY23 with Analysts/Investors held on 10th February, 2023, please find attached herewith the transcript of the aforesaid conference call. The above information is also available on the website of the Company at https://www.themismedicare.com THEMIS MEDICARE LTD. - 530199 - Audio Recording Of The Earnings Conference Call For Q3 & 9M FY23.
Pursuant to Regulation 30 and 46 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that the audio recording of earnings conference call, conducted on February 10th 2023 for the quarter ended December 31, 2022, has been uploaded on the website of the Company at https://www.themismedicare.com/investor-relations/earningcallstranscripts Kindly take the aforesaid on records.